Sunday, September 02, 2018 1:44:47 PM
THIS IS THE REASON FOR THE MESSAGE BOARD!
This post. This research. This poster.
If we are able to have one post as meaningful as this each week, this board retains a purpose.
(We do!, From various sources - thanks all. This one stands out at this point for all the right reasons - it’s what is most useful to see in posts - objective analysis of our investment - whether in the face of a reduced share price or even a well maintained rising price. Facts are facts and never unimportant. And to those who say the facts need to come from the company...I think this post points out that many of these have come directly from the company or from those who work with us, except falconer’s post which is, I believe, based upon his knowledge of the company’s science which he translates for us - thanks.)
Sokol, you are to be commended. Your post is objective, well sourced, obviously well researched, concisely written even with a fountain of pertinent information to investors.
This is worthwhile for every investor or prospective investor to read to remind them of our company’s approach and its potential or to introduce it to some. This should be on the Anavex site, it should be forwarded to industry analysts, journals specific to this field...such as Neurology, and groups associated with Alzheimer’s awareness and finding a cure: End Alzheimer’s, Alzheimer’s Association US/Europe, the Bill Gates Foundation.
My thanks for posting this inordinate amount of facts to refer to, are inadequate. They bolster our commitment to the cause of eradicating this disease and build upon our morale in the company when we see so much evidence before us collectively presented.
This is “The fountain of truth.”
Sincere, but inadequate, thanks, sokol!
* as well as those who supplied explanations and sources cited within
this post
Biostockclub
This post. This research. This poster.
If we are able to have one post as meaningful as this each week, this board retains a purpose.
(We do!, From various sources - thanks all. This one stands out at this point for all the right reasons - it’s what is most useful to see in posts - objective analysis of our investment - whether in the face of a reduced share price or even a well maintained rising price. Facts are facts and never unimportant. And to those who say the facts need to come from the company...I think this post points out that many of these have come directly from the company or from those who work with us, except falconer’s post which is, I believe, based upon his knowledge of the company’s science which he translates for us - thanks.)
Sokol, you are to be commended. Your post is objective, well sourced, obviously well researched, concisely written even with a fountain of pertinent information to investors.
This is worthwhile for every investor or prospective investor to read to remind them of our company’s approach and its potential or to introduce it to some. This should be on the Anavex site, it should be forwarded to industry analysts, journals specific to this field...such as Neurology, and groups associated with Alzheimer’s awareness and finding a cure: End Alzheimer’s, Alzheimer’s Association US/Europe, the Bill Gates Foundation.
My thanks for posting this inordinate amount of facts to refer to, are inadequate. They bolster our commitment to the cause of eradicating this disease and build upon our morale in the company when we see so much evidence before us collectively presented.
This is “The fountain of truth.”
Sincere, but inadequate, thanks, sokol!
* as well as those who supplied explanations and sources cited within
this post
Biostockclub
Recent AVXL News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
